

# Karina Silina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9070863/publications.pdf>

Version: 2024-02-01

37  
papers

3,144  
citations

394421

19  
h-index

414414

32  
g-index

38  
all docs

38  
docs citations

38  
times ranked

5820  
citing authors

#	ARTICLE	IF	CITATIONS
1	HookNet: Multi-resolution convolutional neural networks for semantic segmentation in histopathology whole-slide images. <i>Medical Image Analysis</i> , 2021, 68, 101890.	11.6	92
2	Abstract PO019: CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. , 2021, , .		1
3	CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. <i>Nature Communications</i> , 2021, 12, 769.	12.8	42
4	Renal cell carcinoma pathology in 2021: â€œnew need for renal cancer immune profilingâ€™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	1.8	5
5	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793992.	4.8	14
6	The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 793964.	4.8	13
7	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. <i>Nature Medicine</i> , 2020, 26, 1839-1844.	30.7	245
8	Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5020-5020.	1.6	5
9	Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity. <i>Cell Reports</i> , 2019, 29, 1236-1248.e7.	6.4	187
10	Editorial: Immune Outposts on the Inflammatory Frontier: Tertiary Lymphoid Structures as Targets for Immunotherapy of Cancer and Autoimmunity. <i>Frontiers in Immunology</i> , 2019, 10, 993.	4.8	2
11	A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. <i>Cell</i> , 2019, 177, 1330-1345.e18.	28.9	547
12	Abstract A113: Harnessing lymphoid organ neogenesis as a novel prognostic biomarker and therapeutic target. , 2019, , .		0
13	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 1308-1320.	0.9	238
14	Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1378844.	4.6	179
15	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2660.	4.8	65
16	A Quantitative Pathology Approach to Analyze the Development of Human Cancer-Associated Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2018, 1845, 71-86.	0.9	13
17	An Immune Atlas of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2017, 169, 736-749.e18.	28.9	751
18	The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1564-1574.	2.5	38

#	ARTICLE	IF	CITATIONS
19	The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15083-e15083.	1.6	0
20	High Reproducibility of ELISPOT Counts from Nine Different Laboratories. Cells, 2015, 4, 21-39.	4.1	20
21	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. Cancer Immunology Research, 2015, 3, 1279-1288.	3.4	3
22	Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemotherapy and Pharmacology, 2015, 75, 235-246.	2.3	46
23	Abstract B85: Tertiary lymphoid structures in chemotherapy-treated and untreated lung squamous cell carcinoma patients. , 2015, , .		0
24	Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?. Cancer Immunology, Immunotherapy, 2014, 63, 643-662.	4.2	53
25	Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. Cancer Biomarkers, 2014, 14, 361-369.	1.7	19
26	Log-Normal ELISPOT spot size distribution permits count harmonization among different laboratories. , 2014, 2, .		2
27	Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis in Cancer: An Update. Current Cancer Therapy Reviews, 2014, 9, 227-235.	0.3	3
28	Tumor-associated autoantibody signature for the early detection of gastric cancer. International Journal of Cancer, 2013, 132, 137-147.	5.1	79
29	Sperm-associated Antigens as Targets for Cancer Immunotherapy. Journal of Immunotherapy, 2011, 34, 28-44.	2.4	78
30	Effects of Kaempferol and Myricetin on Inducible Nitric Oxide Synthase Expression and Nitric Oxide Production in Rats. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 461-466.	2.5	21
31	Effects of Lycopene, Indole-3-Carbinol, and Luteolin on Nitric Oxide Production and iNOS Expression are Organ-Specific in Rats. Arhiv Za Higijenu Rada I Toksikologiju, 2010, 61, 275-285.	0.7	13
32	Effects of Indole-3-Carbinol and Flavonoids Administered Separately and in Combination on Nitric Oxide Production and iNOS Expression in Rats. Chinese Medicine, 2010, 01, 5-17.	0.3	3
33	ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring“ even in hands of ELISPOT-inexperienced investigators. Journal of Immunotoxicology, 2009, 6, 227-234.	1.7	58
34	Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients. Journal of Immunological Methods, 2008, 334, 37-50.	1.4	48
35	Autoantibody Profiles as Biomarkers for Response to Therapy and Early Detection of Cancer. Current Cancer Therapy Reviews, 2008, 4, 149-156.	0.3	4
36	Alterations of pre-mRNA splicing in cancer. Genes Chromosomes and Cancer, 2005, 42, 342-357.	2.8	170

#	ARTICLE	IF	CITATIONS
37	Characterisation of tumour-associated antigens in colon cancer. <i>Cancer Immunology, Immunotherapy</i> , 2002, 51, 574-582.	4.2	87